VRDN
Viridian Therapeutics Inc

9,410
Loading...
Loading...
News
all
press releases
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...
Business Wire·7mo ago
News Placeholder
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the companys...
Business Wire·8mo ago
News Placeholder
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data
The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.
Stocktwits·9mo ago
News Placeholder
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive...
Business Wire·9mo ago
News Placeholder
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to...
Business Wire·9mo ago
News Placeholder
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...
Business Wire·10mo ago
News Placeholder
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent...
Business Wire·10mo ago
News Placeholder
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the company or Viridian), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...
Business Wire·10mo ago
News Placeholder
Analyst Expectations For Viridian Therapeutics's Future
Latest Ratings for VRDN DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkInitiates Coverage OnOutperform Nov 2021JMP SecuritiesMaintainsMarket Outperform...
Benzinga·11mo ago

Latest VRDN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.